GYBYS

prnewswire · Jul 4 at 10:27 AM

11:25 ETStrategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics

Yicai · Jun 9 at 08:03 AM

China’s Guangzhou Pharma Expands Central Asia Footprint Through Series of Partnerships

同壁财经 · Jun 2 at 12:35 AM

Chun Guang Intelligent (920810): Won the procurement project of Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd., with a bid amount of 2.397 million yuan

Tip Ranks · Apr 27 at 06:10 AM

Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows Ease

AASTOCKS · Mar 22 at 03:53 AM

"Performance" Baiyunshan's annual net profit is 2.983 billion RMB, an increase of 5.2%, with a final dividend of 0.45 yuan

Wallstreetcn · Jan 27 at 04:41 AM

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited